Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vericel (VCEL – Research Report), Sana Biotechnology (SANA – Research Report) and Lyra Therapeutics (LYRA – Research Report).
Sana Biotechnology (SANA)
In a report released today, Emily Bodnar from H.C. Wainwright assigned a Hold rating to Sana Biotechnology. The company’s shares closed last Wednesday at $3.34, close to its 52-week low of $2.75.
According to TipRanks.com, Bodnar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sana Biotechnology with a $9.67 average price target, a 143.0% upside from current levels. In a report released yesterday, TD Cowen also maintained a Hold rating on the stock.
Lyra Therapeutics (LYRA)
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Lyra Therapeutics, with a price target of $12.00. The company’s shares closed last Wednesday at $2.93.
According to TipRanks.com, Caufield is a 4-star analyst with an average return of
Lyra Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.25, which is a 375.0% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VCEL:
- Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
- Vericel to Present at the Stephens Annual Investment Conference
- Is VCEL a Buy, Before Earnings?
- Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
- Wayfair upgraded, JD.com downgraded: Wall Street’s top analyst calls
